关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
生活·健康·餘暇活動
金融
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
Best-in-class
anticancer
drug
HLB研发的Rivocerenib追求Best-in-class
Rivoceranib为针对癌症优秀的靶向药物
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
IR Letter
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t...
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Press Release
Pharmaceutical firm HLB plans to mo...
Pharmaceutical firm HLB Co. said Wednesday it plans to list its shares on the main bourse, defecting from the secondary...
HLB on a quest for next-generation...
SouthKoreanpharmaceuticalHLBCo.ispoisedtoventureintonewtherapeuticareas,includingchimericantigenreceptorTcell,orCAR-Tcel...
Report
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...